Dianthus Therapeutics DNTH First Selected Antibody — Potential Milestone Payments Due
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept dnth:PotentialMilestonePaymentsDue.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
The Company pays an annual partnered antibody program fee totaling $50 thousand to Alloy. The Company is also obligated to pay a $0.1 million fee to Alloy if the Company sublicenses a product developed with Alloy antibodies or platform assisted antibodies. Upon the achievement, with products developed with Alloy, of (i) certain development milestones and (ii) certain commercial milestones, the Company is obligated to make additional payments to Alloy of up to $1.8 million and $11.0 million, respectively. The Company did not record any amounts owed under the Alloy license agreement during the three months ended March 31, 2026 and 2025.
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's first selected antibody — potential milestone payments due?
- Dianthus Therapeutics (DNTH) reported first selected antibody — potential milestone payments due of $11M in Q1 2026.
- How has Dianthus Therapeutics's first selected antibody — potential milestone payments due changed year-over-year?
- Dianthus Therapeutics's first selected antibody — potential milestone payments due decreased by 0.0% year-over-year, from $11M to $11M.
- What does first selected antibody — potential milestone payments due mean?
- This metric represents the aggregate future financial obligations triggered by the achievement of specific clinical, regulatory, or commercial development milestones for the company's lead antibody candidate. These payments are typically owed to third-party licensors or research partners as the asset progresses through the drug development lifecycle. Monitoring these potential liabilities is essential for assessing the long-term capital requirements and the net economic value of the company's primary pipeline asset.
Ask your AI about Dianthus Therapeutics's first selected antibody — potential milestone payments due.
Connect your AI assistant and compare it to peers, right in your chat.
